EA201992057A1 - PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE - Google Patents

PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE

Info

Publication number
EA201992057A1
EA201992057A1 EA201992057A EA201992057A EA201992057A1 EA 201992057 A1 EA201992057 A1 EA 201992057A1 EA 201992057 A EA201992057 A EA 201992057A EA 201992057 A EA201992057 A EA 201992057A EA 201992057 A1 EA201992057 A1 EA 201992057A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunogenous
peptide
identification
methods
polypeptide
Prior art date
Application number
EA201992057A
Other languages
Russian (ru)
Inventor
Юлианна Лисиэиц
Левенте Мольнар
Эникё Р. Тёке
Йожеф ТОТ
Оршойа Лоринц
Жольт Чисовски
Эстер Шомодьи
Каталин Пантья
Моника Медьеши
Original Assignee
Треош Био Зрт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Треош Био Зрт filed Critical Треош Био Зрт
Priority claimed from PCT/EP2018/055231 external-priority patent/WO2018158456A1/en
Publication of EA201992057A1 publication Critical patent/EA201992057A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к способам идентификации фрагментов полипептида, которые являются иммуногенными для конкретного субъекта-человека, способам получения персонализированных фармацевтических композиций, содержащих такие полипептидные фрагменты, специфическим для субъекта-человека фармацевтическим композициям, содержащим такие полипептидные фрагменты, и способам лечения с использованием таких композиций. Способы включают идентификацию фрагмента полипептида, который связывается с множеством HLA субъекта.The invention relates to methods for identifying fragments of a polypeptide that are immunogenic for a particular human subject, methods for producing personalized pharmaceutical compositions containing such polypeptide fragments, specific for a human subject pharmaceutical compositions containing such polypeptide fragments, and methods of treatment using such compositions. The methods include identifying a fragment of a polypeptide that binds to multiple HLA of a subject.

EA201992057A 2017-03-09 2018-03-02 PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE EA201992057A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1703809.2A GB201703809D0 (en) 2017-03-09 2017-03-09 Vaccine
PCT/EP2018/055231 WO2018158456A1 (en) 2017-03-03 2018-03-02 Personalised immunogenic peptide identification platform

Publications (1)

Publication Number Publication Date
EA201992057A1 true EA201992057A1 (en) 2020-03-06

Family

ID=58605461

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201992057A EA201992057A1 (en) 2017-03-09 2018-03-02 PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE
EA201992059A EA201992059A1 (en) 2017-03-09 2018-03-02 PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL
EA201992058A EA201992058A1 (en) 2017-03-09 2018-03-02 VACCINE

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201992059A EA201992059A1 (en) 2017-03-09 2018-03-02 PLATFORM FOR IDENTIFICATION OF IMMUNOGENOUS PEPTIDES OF THE POPULATION LEVEL
EA201992058A EA201992058A1 (en) 2017-03-09 2018-03-02 VACCINE

Country Status (2)

Country Link
EA (3) EA201992057A1 (en)
GB (1) GB201703809D0 (en)

Also Published As

Publication number Publication date
EA201992059A1 (en) 2020-03-31
GB201703809D0 (en) 2017-04-26
EA201992058A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
CO2019010503A2 (en) Custom immunogenic peptide identification platform
CY1124896T1 (en) ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF
MX2022004072A (en) Factor xi antibodies and methods of use.
DOP2017000047A (en) ANTI-LAG3 ANTIBODIES AND ANTIGEN UNION FRAGMENTS
EA201792501A1 (en) VACCINES FOR THE TREATMENT AND PREVENTION OF CANCER
BR112017017293A2 (en) method for predicting amino acid modifications, for selecting and / or classifying amino acid modifications, and for providing a vaccine and vaccine
BR112019024654A2 (en) binding protein nkg2d, cd16 and ror1 or ror2
CY1121734T1 (en) MUTANT OspA FRAGMENTS AND METHODS AND USES THEREOF
AR110114A1 (en) ANTIBODIES AGAINST b-AMYLOID PIROGLUTAMATO AND ITS USES
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2019003970A (en) Immunogenic arginase peptides.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
EA202192488A1 (en) ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS
EA201992057A1 (en) PERSONALIZED PLATFORM FOR IDENTIFICATION OF AN IMMUNOGENOUS PEPTIDE
ZA202201468B (en) Method